Outpace Bio
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2020
- Type
- Corporation Seattle business license
- Employees
- 74
- Registered name
- Outpace Bio Inc Seattle business license
- Stage
- startup
- Total raised
- $56M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $56M · Jul 2024 SEC Form D
Seattle Biotechs Including Archon and Cyrus Highlight AI's Promise and Pitfalls in Drug Development at 2025 Conference
Seattle biotech leaders at a 2025 conference acknowledged AI's significant potential in drug development while cautioning against overhype. Companies like Archon Biosciences and Cyrus Biotechnology are applying AI to innovate protein design and drug immunogenicity.
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
Seattle Biotech Tune Therapeutics Raises $175M to Advance Epigenetic Editing Trials for Chronic Hepatitis B
Seattle-based biotech startup Tune Therapeutics raised $175 million to support clinical trials of its epigenetic editing treatments for chronic Hepatitis B. The funding will aid development of therapies that control gene expression without altering DNA, leveraging technology developed at Duke University.
University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs
University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.
